SPEEDCELL responds to Europe's medicine shortages by transforming cells-based manufacturing into a rapid, scalable, and cost-effective platform for vaccines and monoclonal antibodies (mAbs). Aligned with the Pharmaceutical Strategy for Europe and HERA’s crisis preparedness goals, the project will optimise cell line development and production processes, targeting the 100 Days Goal for vaccine and therapeutic deployment in health emergencies. By boosting manufacturing capacity and process innovation, SPEEDCELL strengthens Europe’s health resilience and supply security.
- Beneficiaries
Coordinators: Laboratorios Hipra Sa
Participants: Hipra Biotech Services - S.A.U. - Hipra Human Health Sl - Hipra Scientific Sl - Hipra Sociedad Anonima
- Project Location
Spain
- EU funding
€3.9 million
- Funding source
Explore EU innovative projects awarded the STEP Seal. View projects’ details, funding status, and connect with promoters via the interactive dashboard.
Other STEP stories on biotech
In Warsaw, STEP is supporting a pioneering gene therapy for Parkinson’s disease, helping strengthen Europe’s leadership in biotechnology and advanced medical research.
What if diagnosis could be faster, more precise and tailored to each patient? O-MAI is combining AI, imaging and omics sciences to help shape the future of personalised medicine in Europe
PharmSD 3.0 will develop an integrated, continuous-pharmaceutical spray drying process to enhance efficiency, scalability, and cost-effectiveness.